

Title (en)
COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION DER EXPRESSION VON B7 PROTEIN

Title (fr)
COMPOSITIONS ET METHODES DE MODULATION DE L'EXPRESSION DE LA PROTEINE B7

Publication
EP 1631235 A4 20080521 (EN)

Application
EP 04752823 A 20040519

Priority

- US 2004015880 W 20040519
- US 44420603 A 20030523
- US 51061403 P 20031010
- US 52040103 P 20031113
- US 53729104 P 20040116

Abstract (en)
[origin: WO2005000202A2] Antisense oligonucleotide compositions which specifically hybridize with nucleic acids encoding B7 proteins, and use of these compositions for inhibiting expression of B7 mRNA.

IPC 8 full level
A61K 48/00 (2006.01); **A61P 11/06** (2006.01); **C12N 15/113** (2010.01)

IPC 8 main group level
A61K (2006.01)

CPC (source: EP)
A61P 11/06 (2017.12); **C12N 15/1138** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/322** (2013.01); **C12N 2310/3341** (2013.01); **Y02P 20/582** (2015.11)

Citation (search report)

- [PY] WO 03083089 A2 20031009 - PPL THERAPEUTICS SCOTLAND LTD [GB], et al
- [Y] QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 551, XP002474973, ISSN: 0041-1345
- [Y] LIANG X ET AL: "Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345
- [PY] LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", TRANSPLANTATION 27 AUG 2003, vol. 76, no. 4, 27 August 2003 (2003-08-27), pages 721 - 729, XP002474974, ISSN: 0041-1337
- See references of WO 2005000202A2

Citation (examination)

- WO 0074687 A1 20001214 - ISIS PHARMACEUTICALS INC [US], et al
- US 6319906 B1 20011120 - BENNETT C FRANK [US], et al
- WO 03083089 A2 20031009 - PPL THERAPEUTICS SCOTLAND LTD [GB], et al
- DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2001 (2001-02-01), QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity", Database accession no. PREV200100372589
- DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 August 2003 (2003-08-27), LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", Database accession no. NLM12973117
- LIANG X ET AL: "PHENOTYPE AND ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS TREATED WITH ANTISENSE OLIGODEOXYRIBONUCLEOTIDES TARGETING CD80 OR CD86 MRNA", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 33, no. 1/02, 1 February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2005000202 A2 20050106; **WO 2005000202 A3 20060119**; EP 1631235 A2 20060308; EP 1631235 A4 20080521

DOCDB simple family (application)
US 2004015880 W 20040519; EP 04752823 A 20040519